PFS 1144
Alternative Names: EO 122Latest Information Update: 23 Dec 2002
At a glance
- Originator Eisai Co Ltd; Purdue Frederick
- Developer Purdue Frederick
- Class Antiarrhythmics
- Mechanism of Action Calcium channel antagonists; Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Arrhythmias
Most Recent Events
- 23 Dec 2002 Discontinued - Phase-I for Arrhythmias in Japan (unspecified route)
- 23 Dec 2002 Discontinued - Phase-I for Arrhythmias in USA (unspecified route)